These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
790 related articles for article (PubMed ID: 31098866)
21. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy. de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037 [TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of Ki67 in Chinese women diagnosed with ER Hu Y; Gu R; Zhao J; Yang Y; Liu F; Jin L; Chen K; Jia H; Wang H; Liu Q; Su F; Jia W BMC Cancer; 2017 Jan; 17(1):28. PubMed ID: 28061893 [TBL] [Abstract][Full Text] [Related]
23. Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer. Ahn SG; Cha YJ; Bae SJ; Yoon C; Lee HW; Jeong J BMC Cancer; 2018 Mar; 18(1):320. PubMed ID: 29573739 [TBL] [Abstract][Full Text] [Related]
24. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Dieci MV; Mathieu MC; Guarneri V; Conte P; Delaloge S; Andre F; Goubar A Ann Oncol; 2015 Aug; 26(8):1698-704. PubMed ID: 25995301 [TBL] [Abstract][Full Text] [Related]
25. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index. Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822 [TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542 [TBL] [Abstract][Full Text] [Related]
27. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. Ingold Heppner B; Untch M; Denkert C; Pfitzner BM; Lederer B; Schmitt W; Eidtmann H; Fasching PA; Tesch H; Solbach C; Rezai M; Zahm DM; Holms F; Glados M; Krabisch P; Heck E; Ober A; Lorenz P; Diebold K; Habeck JO; Loibl S Clin Cancer Res; 2016 Dec; 22(23):5747-5754. PubMed ID: 27189162 [TBL] [Abstract][Full Text] [Related]
28. Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumors with ER and HER2 positive breast cancer. Zhao Y; Yang N; Wang X; Huang Y; Zhou X; Zhang D Clin Transl Oncol; 2020 Dec; 22(12):2275-2285. PubMed ID: 32447641 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy. Yang X; Rao J; Yang W; Shui R Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444 [TBL] [Abstract][Full Text] [Related]
30. Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer. Zhao CL; Singh K; Brodsky AS; Lu S; Graves TA; Fenton MA; Yang D; Sturtevant A; Resnick MB; Wang Y BMC Cancer; 2019 Nov; 19(1):1036. PubMed ID: 31675929 [TBL] [Abstract][Full Text] [Related]
31. The Role of CXCL13 and CXCL9 in Early Breast Cancer. Razis E; Kalogeras KT; Kotsantis I; Koliou GA; Manousou K; Wirtz R; Veltrup E; Patsea H; Poulakaki N; Dionysopoulos D; Pervana S; Gogas H; Koutras A; Pentheroudakis G; Christodoulou C; Linardou H; Pavlakis K; Koletsa T; Pectasides D; Zagouri F; Fountzilas G Clin Breast Cancer; 2020 Feb; 20(1):e36-e53. PubMed ID: 31699671 [TBL] [Abstract][Full Text] [Related]
32. Novel tumor-infiltrating lymphocytes ultrasonography score based on ultrasonic tissue findings predicts tumor-infiltrating lymphocytes in breast cancer. Fukui K; Masumoto N; Shiroma N; Kanou A; Sasada S; Emi A; Kadoya T; Yokozaki M; Arihiro K; Okada M Breast Cancer; 2019 Sep; 26(5):573-580. PubMed ID: 30868399 [TBL] [Abstract][Full Text] [Related]
33. Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. Tille JC; Vieira AF; Saint-Martin C; Djerroudi L; Furhmann L; Bidard FC; Kirova Y; Tardivon A; Reyal F; Carton M; Vincent-Salomon A Mod Pathol; 2020 Nov; 33(11):2198-2207. PubMed ID: 32404955 [TBL] [Abstract][Full Text] [Related]
34. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications. Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826 [TBL] [Abstract][Full Text] [Related]
35. Clinicopathological features and prognostic analysis of HER2 low and fibrotic focus in HER2-negative breast cancer. Yue M; Wu S; Liu C; Cai L; Wang X; Jia Y; Han D; Liu Y Breast Cancer Res Treat; 2024 Jan; 203(2):373-381. PubMed ID: 37843776 [TBL] [Abstract][Full Text] [Related]
36. Correlation between Murakami W; Tozaki M; Sasaki M; Hida AI; Ohi Y; Kubota K; Sagara Y Eur J Radiol; 2020 Feb; 123():108773. PubMed ID: 31918248 [TBL] [Abstract][Full Text] [Related]
37. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival. Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323 [TBL] [Abstract][Full Text] [Related]
38. On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer. Sinn BV; Sychra K; Untch M; Karn T; van Mackelenbergh M; Huober J; Schmitt W; Marmé F; Schem C; Solbach C; Stickeler E; Tesch H; Fasching PA; Schneeweiss A; Müller V; Holtschmidt J; Nekljudova V; Loibl S; Denkert C Breast Cancer Res; 2024 Sep; 26(1):138. PubMed ID: 39317942 [TBL] [Abstract][Full Text] [Related]
39. Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial. Skriver SK; Jensen MB; Knoop AS; Ejlertsen B; Laenkholm AV Breast Cancer Res; 2020 May; 22(1):46. PubMed ID: 32410705 [TBL] [Abstract][Full Text] [Related]
40. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China. Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]